Ahmed Naguy, Saxby Pridmore, Hend Fm Fr Alenezi, Bibi Alamiri
{"title":"奎硫平和儿科精神病学：证据还是缺乏证据？","authors":"Ahmed Naguy, Saxby Pridmore, Hend Fm Fr Alenezi, Bibi Alamiri","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The atypical antipsychotic, quetiapine has been on market for years now with long track record. In child and adolescent psychiatry, it is FDA-approved for childhood-onset schizophrenia and juvenile bipolar mood disorder. Its attractive pharmacological portfolio speaks to the idea of a versatile pluripotent broad-spectrum psychotropic agent expanding its therapeutic potential on clinical grounds. In this focussed review, authors brief these clinical indications whilst examining the extant evidence.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"31-36"},"PeriodicalIF":0.0000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983474/pdf/","citationCount":"0","resultStr":"{\"title\":\"Quetiapine and Paediatric Psychiatrica: <i>Evidence or Diffidence?</i>\",\"authors\":\"Ahmed Naguy, Saxby Pridmore, Hend Fm Fr Alenezi, Bibi Alamiri\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The atypical antipsychotic, quetiapine has been on market for years now with long track record. In child and adolescent psychiatry, it is FDA-approved for childhood-onset schizophrenia and juvenile bipolar mood disorder. Its attractive pharmacological portfolio speaks to the idea of a versatile pluripotent broad-spectrum psychotropic agent expanding its therapeutic potential on clinical grounds. In this focussed review, authors brief these clinical indications whilst examining the extant evidence.</p>\",\"PeriodicalId\":94351,\"journal\":{\"name\":\"Psychopharmacology bulletin\",\"volume\":\"55 3\",\"pages\":\"31-36\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-04-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983474/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychopharmacology bulletin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharmacology bulletin","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Quetiapine and Paediatric Psychiatrica: Evidence or Diffidence?
The atypical antipsychotic, quetiapine has been on market for years now with long track record. In child and adolescent psychiatry, it is FDA-approved for childhood-onset schizophrenia and juvenile bipolar mood disorder. Its attractive pharmacological portfolio speaks to the idea of a versatile pluripotent broad-spectrum psychotropic agent expanding its therapeutic potential on clinical grounds. In this focussed review, authors brief these clinical indications whilst examining the extant evidence.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
